Skip to content
Participate in our active studiesSubscribe to our Mailing List
AB Science
Masitinib and AB8939 – Two compounds with breakthrough mechanism of action
AB ScienceAB Science
  • Home
  • Company
    • Corporate Overview
    • Executive Commitee
    • Scientific Committee
    • Values
  • Science
    • Overview
    • Masitinib in neurodegenerative disorders
    • Masitinib in inflammatory diseases
    • AB8939 in oncology
    • Publications
  • Pipeline
    • Pipeline Overview
    • Masitinib
      • Multiple Sclerosis
      • Amyotrophic Lateral Sclerosis
      • Alzheimer’s Disease
      • Indolent Systemic Mastocytosis
      • Mast Cell Activation Syndrome
    • AB8939
  • News and Media
    • Press releases
    • In the Media
    • Webcasts
  • Investors
    • Why invest in AB Science
    • Investor Kit
    • Regulated information
      • Annual reports
      • Half-year reports
      • Social and environmental responsabilities
      • Shareholders General Meeting
      • Outstanding shares and voting rights
      • Regulated agreements
      • Board of Directors Charter
      • Information document
    • Stock Information
      • General Information
      • Analyst Coverage
    • Financial Calendar
    • Events
  • Masivet®
    • About Masivet®
    • Medical information and Pharmacovigilance
  • Careers
  • Contact
  • French
  • English
Search:
  • Home
  • Company
    • Corporate Overview
    • Executive Commitee
    • Scientific Committee
    • Values
  • Science
    • Overview
    • Masitinib in neurodegenerative disorders
    • Masitinib in inflammatory diseases
    • AB8939 in oncology
    • Publications
  • Pipeline
    • Pipeline Overview
    • Masitinib
      • Multiple Sclerosis
      • Amyotrophic Lateral Sclerosis
      • Alzheimer’s Disease
      • Indolent Systemic Mastocytosis
      • Mast Cell Activation Syndrome
    • AB8939
  • News and Media
    • Press releases
    • In the Media
    • Webcasts
  • Investors
    • Why invest in AB Science
    • Investor Kit
    • Regulated information
      • Annual reports
      • Half-year reports
      • Social and environmental responsabilities
      • Shareholders General Meeting
      • Outstanding shares and voting rights
      • Regulated agreements
      • Board of Directors Charter
      • Information document
    • Stock Information
      • General Information
      • Analyst Coverage
    • Financial Calendar
    • Events
  • Masivet®
    • About Masivet®
    • Medical information and Pharmacovigilance
  • Careers
  • Contact

Author Archives: Alexis BERNARD

You are here:
  1. Home
  2. Article author Alexis BERNARD

AB Science announces the successful completion of a 2.8 million euros private placement

2025By Alexis BERNARDOctober 17, 2025

17/10/2025 – AB Science announces today the successful completion of a capital increase of a total gross amount of EUR 2.8 million subscribed by a limited number of investors

Summary of the virtual conference held on October 16, 2025

2025By Alexis BERNARDOctober 16, 2025

16/10/2025 – AB Science provides intitial Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid leukemia

AB Science webcast of October 16, 2025

2025By Alexis BERNARDOctober 16, 2025

16/10/2025 – Presentation of the AB Science webcast held on October 16, 2025

AB Science will hold a virtual conference on Thursday, October 16, 2025 from 2pm to 3pm CET to provide an update on the Phase 1 study with AB8939

2025By Alexis BERNARDOctober 14, 2025

14/10/2025 – The purpose of this virtual conference will be to present in more detail the initial clinical data on the combination of AB8939 + venetoclax in the first three patients with refractory and relapsed AML

Revenues for the first half of 2025 and update on AB Science’s activities

2025By Alexis BERNARDOctober 10, 2025

10/10/2025 – AB Science today reports its revenues for the first half of 2025 and provides an update on its activities

AB Science announces a slight delay in the publication of its 2025 half-year financial report

2025By Alexis BERNARDSeptember 30, 2025

30/09/2025 – The Company will publish its financial report for the first half of 2025 on Friday 10 October, 2025, at the latest

AB Science announces the successful completion of a 2.55 million euros private placement

2025By Alexis BERNARDAugust 4, 2025

04/08/2025 – AB Science announces today the successful completion of a capital increase of a total gross amount of EUR 2.55 million subscribed by a limited number of investors

AB Science receives regulatory approval from european countries to initiate third stage of Phase I/II study combining its molecule AB8939 with venetoclax for the treatment of AML

2025By Alexis BERNARDJuly 30, 2025

30/07/2025 – AB Science today announced the approval of the third of four stages of the Phase I/II study with the compound AB8939 in adult patients with relapsed/refractory acute myeloid leukemia

AB Science has received approval from several European countries to initiate the confirmatory phase 3 study of masitinib in ALS

2025By Alexis BERNARDJuly 24, 2025

24/07/2025 – AB Science today announced that the confirmatory Phase 3 study with masitinib in amyotrophic lateral sclerosis has been authorized by the first set of European countries

AB Science announces the successful completion of a EUR 1.925 million private placement

2025By Alexis BERNARDJuly 8, 2025

08/07/2025 – AB Science announces today the successful completion of a capital increase of a total gross amount of EUR 1.925 million subscribed by a limited number of investors

→12345…
67891011121314151617181920212223242526
27→
AB Science
© AB Science – All right reserved
Go to Top